Literature DB >> 12200106

Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats.

P Costelli1, M Bossola, M Muscaritoli, G Grieco, G Bonelli, R Bellantone, G B Doglietto, F M Baccino, F Rossi Fanelli.   

Abstract

The ascites hepatoma Yoshida AH-130 induces loss of body weight and tissue waste. Tumour necrosis factor alpha (TNF-alpha) plays a pivotal role in the pathogenesis of muscle wasting in this model system, but other cytokines, such as interleukin-6, may be involved. In order to verify whether a combined anticytokine treatment may synergistically counteract muscle protein degradation, tumour bearing rats were treated with pentoxyfilline (PTX, an inhibitor of TNF-alpha synthesis), or with suramin (SUR, an antiprotozoal drug blocking the peripheral action of several cytokines including IL-6 and TNF-alpha), or both the drugs, and the effects on muscle proteolytic systems were assessed. Muscle protein loss in the AH-130-bearing rats was associated with increased activity of both the ATP-ubiquitin- and the calpain- dependent proteolytic pathways (246% and 230% of controls, respectively). Both PTX and SUR, either alone or in combination, prevented the depletion of muscle mass and significantly reduced the activity of muscle proteolytic systems. In particular, treatment with SUR, either alone or with PTX, induced a decrease in enzymatic activities to values similar to those of controls. The results obtained in the present paper demonstrate that: (i) muscle depletion in this model is indeed associated with increased proteasome- and calpain-dependent proteolysis, as previously suggested by increased mRNA expression of molecules pertaining to both pathways; (ii) anticytokine treatments effectively reduce muscle protein loss by down-regulating the activity of at least two major proteolitic systems; (iii) SUR is more effective than PTX in reducing the activity of proteolytic systems, possibly because of its multiple anticytokine action.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200106     DOI: 10.1006/cyto.2002.1036

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  19 in total

Review 1.  Calpain activity and muscle wasting in sepsis.

Authors:  Ira J Smith; Stewart H Lecker; Per-Olof Hasselgren
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-05-20       Impact factor: 4.310

Review 2.  Energy homeostasis and cachexia in chronic kidney disease.

Authors:  Robert H Mak; Wai Cheung
Journal:  Pediatr Nephrol       Date:  2006-08-01       Impact factor: 3.714

Review 3.  The "parallel pathway": a novel nutritional and metabolic approach to cancer patients.

Authors:  Maurizio Muscaritoli; Alessio Molfino; Gianfranco Gioia; Alessandro Laviano; Filippo Rossi Fanelli
Journal:  Intern Emerg Med       Date:  2010-07-02       Impact factor: 3.397

4.  Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies.

Authors:  Elisabetta Gazzerro; Stefania Assereto; Andrea Bonetto; Federica Sotgia; Sonia Scarfì; Angela Pistorio; Gloria Bonuccelli; Michele Cilli; Claudio Bruno; Federico Zara; Michael P Lisanti; Carlo Minetti
Journal:  Am J Pathol       Date:  2010-03-19       Impact factor: 4.307

5.  Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.

Authors:  Aminah Jatoi; Steven R Alberts; Nathan Foster; Roscoe Morton; Patrick Burch; Margaret Block; Phuong L Nguyen; John Kugler
Journal:  Support Care Cancer       Date:  2005-03-10       Impact factor: 3.603

6.  The effects of pentoxifylline on skeletal muscle contractility and neuromuscular transmission during hypoxia.

Authors:  Fatma Simsek-Duran; Mert Ertunc; Rustu Onur
Journal:  Indian J Pharmacol       Date:  2009-10       Impact factor: 1.200

7.  Role of NF-kappaB and cytokine in experimental cancer cachexia.

Authors:  Wei Zhou; Zhi-Wei Jiang; Jie Tian; Jun Jiang; Ning Li; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

8.  Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc ( Min/+ ) mouse.

Authors:  Kristen A Baltgalvis; Franklin G Berger; Maria Marjorette O Peña; J Mark Davis; James P White; James A Carson
Journal:  Pflugers Arch       Date:  2008-08-19       Impact factor: 3.657

9.  The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse.

Authors:  James P White; John W Baynes; Stephen L Welle; Matthew C Kostek; Lydia E Matesic; Shuichi Sato; James A Carson
Journal:  PLoS One       Date:  2011-09-19       Impact factor: 3.240

10.  Cancer cachexia: impact, mechanisms and emerging treatments.

Authors:  Vanessa C Vaughan; Peter Martin; Paul A Lewandowski
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-10-25       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.